Medical News

RSS

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test.

19 May 2011

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

From Thermo Fisher Scientific Inc. 19 May 2011

First Edition: May 19, 2011

Today's headlines continue to analyze the impact of the departure of Sen. Tom Coburn, R-Okla., from the 'Gang of Six' on the efforts to address long-term budget issues such as Medicare spending.

19 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Study explores link between specific temperament traits and clinical events after heart attack

This study explores for the first time the potential predictive power of Cloninger's temperament traits on prognosis in patients after an acute coronary syndrome admission.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Centric Health enters agreements to acquire Blue Water Surgical & Medical Centres, LSC

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into agreements to acquire substantially all of the assets of Blue Water Surgical Centre Ltd., Blue Water Rejuvenation Inc., Blue Water Diagnostics Ltd. and Windsor Endoscopy Centre Ltd., along with 75% of the issued and outstanding securities of the London Scoping Centre.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

MAXIMUS wins Title IV-E Foster Care and Adoption Assistance contract in Wisconsin

MAXIMUS, a leading provider of government services worldwide, announced today that its Human Services North America Division has won a renewal of its Title IV-E Foster Care and Adoption Assistance contract with the Wisconsin Department of Children and Families.

19 May 2011

Online program helps people to manage chronic pain

There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition.

19 May 2011

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its first quarter ended March 31, 2011.

19 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

Shamir Optical Industry first quarter revenues increase 12.8% to $45.2 million

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the first quarter ended March 31, 2011.

19 May 2011

Caring Online offers comprehensive and informative website on adult eating disorders

Are you aware that eating disorders affect more than 10 million people in this country, and that bulimia, anorexia, binge eating and other destructive food behaviors are not exclusive to the youth? These serious and often deadly afflictions have become a growing problem with midlife adults and older, often more difficult to detect as adults are expected to have it "all together."

19 May 2011

Center for Companies That Care names UHC as 2011 Honor Roll

Center for Companies That Care has announced that University HealthSystem Consortium was named to its Honor Roll, a national list recognizing employers for outstanding workplace practices and active community involvement, for the eighth consecutive year.

19 May 2011

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research.

19 May 2011

Medical News

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

First Edition: May 19, 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Study explores link between specific temperament traits and clinical events after heart attack

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Centric Health enters agreements to acquire Blue Water Surgical & Medical Centres, LSC

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

MAXIMUS wins Title IV-E Foster Care and Adoption Assistance contract in Wisconsin

Online program helps people to manage chronic pain

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Shamir Optical Industry first quarter revenues increase 12.8% to $45.2 million

Caring Online offers comprehensive and informative website on adult eating disorders

Center for Companies That Care names UHC as 2011 Honor Roll

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News